HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.

AuthorsPellegrino Musto, Vincenzo Ludovico Fraticelli, Giovanna Mansueto, Emanuela Madonna, Andrea Nozza, Alessandro Andriani, Alberto Mussetti, Stelvio Ballanti, Velia Bongarzoni, Anna Baraldi, Francesca Patriarca, Donatella Vincelli, Antonietta Falcone, Daniele Derudas, Catello Califano, Renato Zambello, Giuseppe Mele, Alberto Fragasso, Luca Baldini, Sergio Storti
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 56 Issue 5 Pg. 1510-3 (May 2015) ISSN: 1029-2403 [Electronic] United States
PMID25651428 (Publication Type: Letter)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Bendamustine Hydrochloride
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Alkylating (administration & dosage, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bendamustine Hydrochloride (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma (diagnosis, drug therapy, mortality, pathology)
  • Neoplasm Staging
  • Recurrence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: